author-photo

Vikram Sinha

Merck & Co.
Eli Lilly and Company
Food and Drug Administration

80

Papers

1635

Citations

Citation Trend

Filter By

Papers (56) Sort By

Journal Conference Others

Abstract CT143: Pembrolizumab bioavailability after subcutaneous administration: analysis from the KEYNOTE-555 Cohort A in metastatic melanoma

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (1)
An integrated approach to competition regulation and data protection in India

2021 CSI Transactions on ICT
- Vikram Sinha
- Sharmadha Srinivasan
Show All
- Source
- Cite
- Save
Citations (0)
A disease progression model to quantify the non-motor symptoms of Parkinson's disease in participants with leucine-rich repeat kinase 2 mutation.

2021 Clinical Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (1)
An elevated C-reactive protein level in an inpatient rehabilitation setting after joint replacement: To act or not to act? - that is the question.

2021 Medicine
Show All
- Source
- Cite
- Save
Citations (0)
Regulating digital ecosystems: bridging the gap between competition policy and data protection

2021 Industrial and Corporate Change
Show All
- Source
- Cite
- Save
Citations (3)
Pivotal Dose of Pembrolizumab - A Dose Finding Strategy for Immuno-Oncology.

2021 Clinical Pharmacology & Therapeutics
Show All
- Source
- Cite
- Save
Citations (2)
Corrigendum to "A six-weekly (Q6W) dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation" [Eur J Canc 131 (2020) 68-75].

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Extrapolation of Adult Efficacy to Pediatric Patients With Chemotherapy‐Induced Nausea and Vomiting

2020 The Journal of Clinical Pharmacology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT042: Pembrolizumab 400 mg Q6W dosing: First clinical outcomes data from Keynote-555 cohort B in metastatic melanoma patients

2020 Tumor Biology
Show All
- Source
- Cite
- Save
Citations (11)
Generation of a comprehensive disease progression model across the Alzheimer’s disease continuum: Human/Trial design

2020 Alzheimers & Dementia
Show All
- Source
- Cite
- Save
Citations (0)